Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MXCT

MXCT - MaxCyte, Inc. Stock Price, Fair Value and News

$1.01-0.06 (-5.61%)
Market Closed

46/100

MXCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

46/100

MXCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.17

Target 3M

$1.16

Target 6M

$1.16

MXCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MXCT Price Action

Last 7 days

-17.9%

Last 30 days

-36.1%

Last 90 days

-33.1%

Trailing 12 Months

-78.4%

MXCT RSI Chart

MXCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MXCT Valuation

Market Cap

107.7M

Price/Earnings (Trailing)

-2.36

Price/Sales (Trailing)

3.13

EV/EBITDA

-2.29

Price/Free Cashflow

-2.61

MXCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.17

Target 3M

$1.16

Target 6M

$1.16

MXCT Fundamentals

MXCT Revenue

Revenue (TTM)

34.4M

Rev. Growth (Yr)

-16.35%

Rev. Growth (Qtr)

-19.72%

MXCT Earnings

Earnings (TTM)

-45.6M

Earnings Growth (Yr)

-7.43%

Earnings Growth (Qtr)

-0.48%

MXCT Profitability

Operating Margin

91.49%

EBT Margin

-132.58%

Return on Equity

-25.31%

Return on Assets

-21.38%

Free Cashflow Yield

-38.26%

MXCT Investor Care

Shares Dilution (1Y)

1.13%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202537.7M35.8M34.4M0
202444.1M45.4M45.6M38.6M
202341.2M40.7M38.0M41.3M
202239.0M41.5M42.0M44.3M
202126.9M28.9M32.3M33.9M
2020023.1M24.7M26.2M
201900021.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About MaxCyte, Inc.

MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEhttps://maxcyte.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES125

MaxCyte, Inc. Frequently Asked Questions

MXCT is the stock ticker symbol of MaxCyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of MaxCyte, Inc. is 107.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MXCT's fair value in chart for subscribers.

The fair value guage provides a quick view whether MXCT is over valued or under valued. Whether MaxCyte, Inc. is cheap or expensive depends on the assumptions which impact MaxCyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MXCT.

As of Wed Jan 28 2026, MXCT's PE ratio (Price to Earnings) is -2.36 and Price to Sales (PS) ratio is 3.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MXCT PE ratio will change depending on the future growth rate expectations of investors.